Price (delayed)
$0.2039
Market cap
$20.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.35
Enterprise value
-$446,092
Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin
There are no recent dividends present for PIRS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.